other body parts via the lymphatic system Current treatment for LAM is oral Rapamycin, which is limited by its low bioavailability (~15%) and side effects [1, 2]. It’s been ... lymphatic system [3]. Aim: The current…
goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of AD-like symptoms in pre-symptomatic…
data showed that the expression of the reduced gene list in the presence of Rapamycin, significantly increased based on RNASeq data in TNBC subtype compared to the other two subtypes ... presence of 3000 µg/mL Rapamycin…
extensive mutation work has been carried out to improve the rapamycin (antibiotic) yield by Streptomyces ghanaensis MTCC 4003. Mutational approach i.e., sequential UV mutagenesis was applied to the spores with…
Objective: We aimed to examine the outcomes associated with the mammalian target of rapamycin inhibitor (sirolimus or everolimus), (m-TORi) regimens in kidney transplant recipients (KTR) with primary diagnoses
protein (mTOR) has been found to promote cellular senescence by different pathways and rapamycin (the inhibitor of TORC1) shows potential in delaying this processes, and hence ageing. In this research ... investigated…
developing a strate gy for the sustained perivascular delivery of an antiprolifera tive agent, rapamycin, using an injectable biodegra dable polymer, ReGel ® . In this study we examined the in-vitro ... kinetics of…
study was to investigate the pronouncement and type of interaction of complex administration of rapamycin – blocker of mTOR, pioglitazone - agonist of PPAR-gamma, and minocycline hydrochloride – suppression of microglia…
Rapamycin, a metabolite of Streptomyces hygroscopicus, has a wide range of therapeutic applications in medicine. However, the possibility of its use is significantly limited, since the existing natural strains ... 20SS…
determine the effects of enhanced autophagy on neural apoptosis in rat SCI model. Rapamycin or vehicle was given via an intraperitoneal injection after SCI. Spinal cord samples were extracted ... significantly reduced…
Rapamycin and its analogs (rapalogs), those are the mTOR inhibitor, exhibit immunosuppressant and antitumor activity, and extend survival of patients with metastatic renal-cell carcinoma (mRCC), advanced breast cancer…
effect of Silymarin on proliferation and apoptosis of human T cells in comparison with Rapamycin and FK506. Peripheral Blood Mononuclear Cells (PBMCs) from healthy individuals were activated with ... 5μg/ml) and then…
mammalian target of rapamycin (mTOR) is a promising target molecule for cancer therapy. The mTOR signaling pathway plays important roles on cell growth and angiogenesis in tumor progression ... also PTEN-positive tumor…
cancer and its relationship with the adenosine-monophosphate activated-protein kinase-mammalian target of rapamycin signaling pathway were investigated in this work. The ACT-1 thyroid cancer cell lines were ... thyroid…
Objective: To explore the influences of rapamycin on cardiomyocyte autophagy level of early Heart Failure (HF) rat. Methods: HF rat model was built by abdominal aorta surgery, and then they ... control group. The…
evaluate a single-step, organic solvent-free supercritical fluid process for the preparation of rapamycin-methyl-β-cyclodextrin complexes with an express goal to enhance the dissolution properties of rapamycin…
different dose, and regulated the EAMMH induced immune memory response by treatment with rapamycin, an immune suppressive drug, and IL-28B, a cytokine down-regulating regulatory T cells ... dose of EAMMH showed higher…
stents in preventing bacterial adhesion-associated infection and restenosis was achieved. Thus, a rapamycin-heparin coated drug with a cyclodextrin carrier can be considered as a novel product
safety and efficacy of a therapeutic regimen including sorafenib and mammalian target of rapamycin inhibitors (mTORi) in this setting. The medical charts of the recipients of a LT presenting
human LAM/TSC cells to the uterus. We also examined the action of rapamycin and anti-Epidermal Growth Factor Receptor (EGFR) antibody. LAM/TSC cells were endonasally administered ... groups: control, LAM/TSC…